dr. mcdermott on immunotherapy as a standard of care in rcc
Published 6 years ago • 129 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
58:31
audio version uronurse episode 106: new immunotherapy approaches for bladder cancer
-
1:28:18
navigating evolving standards of care in rcc: novel targeted and immunotherapy options
-
4:04
a novel cxcr4 inhibitor for rcc and a novel immunotherapy endpoint | david mcdermott
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
1:08
mcdermott: immunotherapy agents in renal cell carcinoma
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:11
dr. motzer on the milestone of immunotherapy in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc